Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 1/20 | 0.37 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.37 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | NPC1 | O15118 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12385739 | 0.78 | MAPT (0.44) | CYP2D6KCNH2HRH3KMT2AMAPT | |
| SCHEMBL23710964 | 0.69 | OPRK1 (0.33) | MAPT | |
| SCHEMBL23710885 | 0.68 | NOS3 (0.37) | MEN1KMT2A | |
| SCHEMBL25117840 | 0.67 | MAPT (0.31) | MAPT | |
| SCHEMBL25822492 | 0.67 | — | — | |
| SCHEMBL21025310 | 0.66 | HRH3 (0.50) | CYP2D6KCNH2HRH3 | |
| SCHEMBL4099236 | 0.66 | HRH3 (0.50) | CYP2D6KCNH2HRH3 | |
| SCHEMBL1104717 | 0.66 | HRH3 (0.50) | CYP2D6KCNH2HRH3 | |
| SCHEMBL12384346 | 0.65 | MAPT (0.52) | KMT2AMAPT | |
| SCHEMBL179369 | 0.65 | HRH3 (0.63) | CYP2D6KCNH2HRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11746120-B2 | Stat degraders and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2023-09-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11746120-B2 | Stat degraders and uses thereof | STAT4, STAT1, STAT3 | CYP2D6 698/4885KCNH2 4870/4885HRH3 4371/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.